anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, we present a computational framework designed to evaluate virtual scenarios of cardiac resynchronization therapy (CRT) and compare their effectiveness based on relevant clinical biomarkers. Our approach involves electro-mechanical numerical simulations personalized, for patients with left bundle branch block, by means of a calibration obtained using data from Electro-Anatomical Mapping System (EAMS) measures acquired by cardiologists during the CRT procedure, as well as ventricular pressures and volumes, both obtained pre-implantation. We validate the calibration by using EAMS data coming from right pacing conditions. Three patients with fibrosis and three without are considered to explore various conditions. Our virtual scenarios consist of personalized numerical experiments, incorporating different positions of the left electrode along reconstructed epicardial veins; different locations of the right electrode; different ventriculo-ventricular delays. The aim is to offer a comprehensive tool capable of optimizing CRT efficiency for individual patients. We provide preliminary answers on optimal electrode placement and delay, by computing some relevant biomarkers such as d P / d t max    , ejection fraction, stroke work. From our numerical experiments, we found that the latest activated segment during sinus rhythm is an effective choice for the non-fibrotic cases for the location of the left electrode. Also, our results showed that the activation of the right electrode before the left one seems to improve the CRT performance for the non-fibrotic cases. Last, we found that the CRT performance seems to improve by positioning the right electrode halfway between the base and the apex. This work is on the line of computational works for the study of CRT and introduces new features in the field, such as the presence of the epicardial veins and the movement of the right electrode. All these studies from the different research groups can in future synergistically flow together in the development of a tool which clinicians could use during the procedure to have quantitative information about the patient's propagation in different scenarios.
Ompenaclid (RGX-202-01) 3000mg PO (tablets) BID; Irinotecan: 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, followed by 5-FU 2400 mg/m2 over 46 hours, on Days 1 and 15 of each 28-day cycle. Bevacizumab: 5 mg/kg on Days 1 and 15 of each 28-day cycle.
Disclosed are dermatological or cosmetic cream, serum and toner compositions and methods thereof for use in promoting healthy skin. A dermatological composition (cream, toner and serum) is applied to the skin to promote optimal health of the skin. The preferred cream composition is comprised of, reduced glutathione and/or cysteinylglycine, ascorbyl glucoside in a dermatologically acceptable carrier containing a salt composition. Preferably, the salt composition contains sodium, magnesium, potassium and calcium. The cream formulations are optionally ionically balanced. Preferably, potassium chloride, magnesium chloride, calcium chloride, magnesium sulfate and potassium phosphate are present in sufficient amounts. Toner composition contains sodium, magnesium, potassium and calcium ions and optionally bicarbonate ions and preservative(s). The toner formulations are optionally ionically balanced. The preferred serum composition contains ascorbyl glucoside and /or ascorbic acid in a carrier. Methods of manufacture of these compositions are also disclosed.
The invention discloses a fracture setting capsule. The fracture setting capsule is invented for solving the problems that in the prior art, the curative effect is poor, and taking is inconvenient. The fracture setting capsule comprises more than twenty medicines including angelica sinensis, rhizoma corydalis, pseudo-ginseng, ligusticum wallichii, radix stephaniae tetrandrae, roots of common peony, endothelium corneum gigeriae galli, ground beeltle, rhizoma drynariae, cinnamon, frankincense, myrrh, fritillaria thun-bergli, cassia twig, safflower carthamus, radix angelicae pubescentis, musk and the like. The fracture setting capsule has the effects that both manifestation and root cause of diseases are treated, reunion of bone is achieved, tendon relaxtion and activeation of blood circulation are achieved, diminish inflammation and pain stopping are achieved, digestion is aided, and fracture healing is rapid. The fracture setting capsule is mainly used for treating traumatic injuries, fractures, rarefaction of bone and osteonecrosis; the effect for treating comminuted fractures on the parts of the neck, the waist, the thoracic vertebra and the like is particularly good, and the effect on hyperostosis and arthritis is excellent. The curing rate reaches 99%.
Cerebrovascular fragility and cerebral microhemorrhages (CMH) contribute to age-related cognitive impairment, mobility defects, and vascular cognitive impairment and dementia, impairing healthspan and reducing quality of life in the elderly. Insulin-like growth factor 1 (IGF-1) is a key vasoprotective growth factor that is reduced during aging. Circulating IGF-1 deficiency leads to the development of CMH and other signs of cerebrovascular dysfunction. Here our goal was to understand the contribution of IGF-1 signaling on vascular smooth muscle cells (VSMCs) to the development of CMH and associated gait defects. We used an inducible VSMC-specific promoter and an IGF-1 receptor (Igf1r) floxed mouse line (Myh11-CreERT2 Igf1rf/f) to knockdown Igf1r. Angiotensin II in combination with L-NAME-induced hypertension was used to elicit CMH. We observed that VSMC-specific Igf1r knockdown mice had accelerated development of CMH, and subsequent associated gait irregularities. These phenotypes were accompanied by upregulation of a cluster of pro-inflammatory genes associated with VSMC maladaptation. Collectively our findings support an essential role for VSMCs as a target for the vasoprotective effects of IGF-1, and suggest that VSMC dysfunction in aging may contribute to the development of CMH.
The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. In addition, extrapancreatic effects may also play a role in the activity of sulfonylureas such as glimepiride. This is supported by both preclinical and clinical studies demonstrating that glimepiride administration can lead to increased sensitivity of peripheral tissues to insulin. These findings are consistent with the results of a long-term, randomized, placebo-controlled trial in which glimepiride therapy improved postprandial insulin/C-peptide responses and overall glycemic control without producing clinically meaningful increases in fasting insulin/C-peptide levels. However, as with other sulfonylureas, the mecha­nism by which glimepiride lowers blood glucose during long-term admin­istration has not been clearly established.

Glimepiride is effective as initial drug therapy. In patients where monotherapy with glimepiride or metformin has not produced adequate glycemic control, the combination of glimepiride and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different primary mechanisms of action. This complementary effect has been observed with metformin and other sulfonylureas, in multiple studies.
Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
It was determined that 76 babies with BPBI and their families applied to our hospital for their first medical check or examination. Inclusion criteria: a diagnosis of BPBI, initial evaluation and not having started treatment before, being in the age range of 15-90 days old, and consent to participate in the study. Exclusion criteria: Children with BPBI who are older than 90 days or younger than 15 days and have started regular physical therapy or home program before applying to our hospital. In addition, causes of pseudo-paralysis that are diseases that may show symptoms similar to BPBI were excluded. Seventeen children who were excluded because they did not meet the inclusion criteria. Hence, 59 children with BPBI were included in the study.
In vitro metabolism studies showed that CYP1A2 is the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with ropinirole, adjustment of the dose of ropinirole may be required. 

Coadministration of ciprofloxacin, an inhibitor of CYP1A2, with immediate-release ropinirole increased the AUC of ropinirole by 84% on average and Cmax by 60% [see Clinical Pharmacology (12.3)]. 

Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking. In one study in patients with Restless Legs Syndrome, cigarette smokers had an approximate 30% lower Cmax and a 38% lower AUC than did nonsmokers, when those parameters were normalized for dose. 

There is no evidence of interaction between ropinirole and other CYP1A2 substrates (e.g., theophylline). 

Ropinirole and its circulating metabolites do not inhibit or induce P450 enzymes therefore ropinirole is unlikely to affect the pharmacokinetics of other drugs by a P450 mechanism [see Clinical Pharmacology (12.3)].
Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a \>/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
The proposed study is a multi-site, three-arm randomized controlled trial of a mindfulness-based intervention for Chinese family caregivers in Hong Kong. Effects of the intervention will be compared with those of an evidence-based psychoeducation program, and treatment-as-usual. 240 caregivers of frail elderly with moderate to severe levels of frailty, will be recruited and randomly assigned to mindfulness-based intervention, psychoeducation, and treatment-as-usual experimental conditions. Overall program effectiveness will be analyzed on measures of caregiver burden, depression, anxiety, positive caregiving experience, spirituality, family conflict, and the biomarker of heart rate variability. Measures on coping styles, experiential avoidance, and self-efficacy will be explored to see if they mediate the changes to participant improvements in outcomes. 6-month follow-up will be included to investigate the maintenance effects.
Hypoglycemia is the most common adverse reaction of insulin therapy, including LEVEMIR. The risk of hypoglycemia increases with intensive glycemic control. Patients must be educated to recognize and manage hypoglycemia. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person or parenteral glucose infusion, or glucagon administration has been observed in clinical trials with insulin, including trials with LEVEMIR.

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), exercise, and concomitant medications may also alter the risk of hypoglycemia [see Drug Interactions (7)]. 

The prolonged effect of subcutaneous LEVEMIR may delay recovery from hypoglycemia. 

As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes, diabetic neuropathy, use of medications such as beta-blockers, or intensified glycemic control [see Drug Interactions (7)]. These situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior to the patient’s awareness of hypoglycemia.
PURPOSE: To prevent and improve the epidermolysis of Fugu rubripesrubripes by improving the anemia of the Fugu rubripesrubripes on the culture of the Fugu rubripesrubripes. CONSTITUTION: Glutathione, preferably a glutathione-containing yeast, is contained in an amount of 0.2-100mg/kg. The glutathione-containing yeast preferably contains the glutathione in an amount of 1-15%, and the used yeast includes torula yeast and bread yeast. The glutathione is administered at a daily dose of 0.2-100mg, preferably 5-100mg, per kg of the body of the Fugu rubripesrubripes. When the healthy state of the Fugu rubripesrubripes is bad or when the epidermolysis appears on the Fugu rubripesrubripes, the glutathione is administered approximately 5-20 times continuously or once in several days. The administration method is performed by adding the glutathione together with Mysis and and formula feeds to fish such as sand lance, saurel or sardine, pelletizing the mixture and subsequently administering the obtained moist pellets.
Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
The investigators will evaluate the block-prolonging efficacy of dexamethasone 1 mg in supraclavicular blocks. The investigators will be answering essentially two questions. First, how long do supraclavicular blocks last when low dose dexamethasone is used as an adjunct. Only one study has looked at doses this low (Liu et al. 2015). Some methodological problems with this study include evaluation of shoulder surgery using supraclavicular blocks, which may or may not cover the posterior port site; use of the endpoint of "time to first analgesic", which may or may not indicate actual block duration; and low numbers powered to 80%, which may yield spurious results. To avoid these issues the investigators chose upper limb surgery, a type of block which will definitely cover the entire surgical site, and an endpoint of time to first pain at surgical site, regardless of whether analgesic is needed. The investigators are also powering to 95% and recruiting higher numbers of patients.

The second question evaluates the efficacy of 1 mg of intravenous dexamethasone. The study is powered to address this question, but in doing so is also powered adequately to address the first question. Studies to date have mixed results and methodological errors. No other studies have evaluated this dose of intravenous dexamethasone.
Insults to vital organs have serious and even life-threatening consequences. Organ insults have different etiologies and typically include drugs, toxins and ischemic insults. Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular feedback regulator of autophagy. Here, the inventors report that injection of a monoclonal antibody neutralizing ACBP/DBI (α-DBI) protects the murine liver against ischemia/reperfusion damage, acute intoxication by acetaminophen and concanavalin A, as well as against liver fibrosis induced by bile duct ligation or carbon tetrachloride. Of note, the results support the contention that α-DBI mediates broad organ-protective effects against multiple insults. Thus, the present invention relates to methods and pharmaceutical composition of protecting organs from injuries comprising neutralization of Acyl-CoA Binding Protein.
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine capsule for treating the spleen deficiency and liver stagnation symptom and a preparation method thereof. The traditional Chinese medicine capsule is prepared from the following traditional Chinese medicine raw materials in parts by weight: 7 to 10 parts of roasted rhizoma atractylodis macrocephalae, 7 to 10 parts of parched white peony root, 5 to 8 parts of roasted pericarpium citri reticulatae and 3 to 5 parts of Chinese parsnip root. The preparation method comprises the following steps: weighing the raw materials in parts by weight, smashing the raw materials to form fine powder to pass a sieve of 80 to 100 meshes, then filling medical powder into each empty capsule to reach the weight of 0.6g to 0.7g, and putting the capsules in a bottle and sealing. The traditional Chinese medicine capsule can be used for effectively treating the spleen deficiency and liver stagnation symptom, and has the functions of soothing liver-qi stagnation and invigorating spleen-stomach and replenishing qi under the recuperating actions of the traditional Chinese medicines so as to treat both manifestation and root causes of the spleen deficiency and liver stagnation symptom. Thus, the side effects of western medicines are avoided, and the digestive ability of digestive tracts is completely restored. As a result, the health of a patient is regained.
PURPOSE: To obtain the subject compd. useful as an inhalation anesthetic from an inexpensive starting substance through a new intermediate in low cost by reacting sulfur tetrafluoride with new dichloromethoxy-α-chloroacetyl chloride at high temp.  
     CONSTITUTION: A new substance represented by formula I is reacted with SF 4  at high temp. to advantageously obtain objective compds represented by formulae II and III. If the objective compd. represented by the formula III is reacted with a fluorinating agent, it can be converted to the objective compd. represented by the formula II. The new substance represented by the formula I can be obtained by reacting an inexpensive compd. represented by formula IV in the presence of chlorine gas and light energy in the presence or absence of an org. solvent at temp. from about -15°C to a b.p. of a solvent (about 50°C in the absence of the solvent) and a new substance represented by formula V formed at the same time is also reacted with SF 4  and, if the obtained compd. represented by formula VI is reacted with chlorine gas in the presence of light energy, it can be converted to the objective compd. represented by the formula II. 
     COPYRIGHT: (C)1990,JPO
Successful long-term control of hyperglycemia decreases the risk for diabetic complications . Although a family history of diabetes is an established risk factor for type 2 diabetes, lifestyle factors also play an important role in its cause . However, physicians are poorly informed about how their patients' alcohol use affects risk for or management of diabetes. Moderate alcohol consumption has been associated with lower risk of both cardiovascular disease and type 2 diabetes, and is also linked to lower cardiovascular risk among type 2 diabetics. Potential mechanisms have focused primarily on lipid metabolism, coagulation, fibrinolysis, and insulin sensitivity. A recent systematic review of the literature to assess the effect of alcohol consumption on risk for and management and complications of diabetes mellitus suggests that moderate alcohol consumption is associated with a decreased risk for diabetes, whereas heavy alcohol consumption may be associated with an increased risk. Our aim is to assess the effect of moderate alcohol intake on glycemic control and cardiovascular disease mediators among patients with type 2 diabetes.
BACKGROUND: Cardiac fibromas are extremely rare in adults. The preferred treatment is surgical resection, but antiarrhythmic medications or heart transplantation have also been used previously. The cardiac imaging, particularly MRI, can be useful to help delineate between primary cardiac tumors, and surgical factors such as the extent/size of the fibroma, involvement of the coronary arteries or mitral apparatus and amount of residual myocardium influence whether surgical resection is feasible.
CASE PRESENTATION: A 42-year-old male presented with a wide-complex tachycardia, unresponsive to amiodarone. An echocardiogram was performed which showed a possible posterior wall mass. A cardiac MRI showed a well circumscribed lateral wall intracardiac fibroma, measuring 5.2 × 5.1 × 3.8 cm with preserved function. Surgical resection was successful, and he was discharged without a defibrillator.
CONCLUSIONS: Cardiac fibromas are encapsulated tumors which do not infiltrate myocardium and should be surgically resected if possible.
Location data associated with a cardiac wall motion during a cardiac cycle can be received. The cardiac cycle can be divided into incremental phases. The location data associated with the cardiac wall motion can be assigned to the incremental phases. A fiducial pair of coordinates can be determined for each of the incremental phases. The fiducial pair of coordinates can include location data for an intermediate cardiac phase and location data for a reference cardiac phase. A fiducial loop can be determined from the fiducial pair of coordinates for each of the incremental phases. A learned cardiac mapping between the reference cardiac phase and the intermediate cardiac phase can be determined using the fiducial loop.
PURPOSE: A composition containing a Salvia plebeia R.Br extract for preventing and treating atherosclerosis is provided to reduce foam cell formation and to promote the release of cholesterol to the outside. CONSTITUTION: A composition for preventing and treating atherosclerosis contains a Salvia plebeia R. Br. extract as an active ingredient. The extract is prepared by mixing water, alcohol, acetone, hexane, ethyl acetate, or a mixture thereof with Salvia plebeia R. Br. and heating at 60-70 deg.C. for 3-5 hours; a step of filtering and concentrating; and a step of freeze-drying.
Coupling red blood cell (RBC) supply to O2 demand is an intricate process requiring O2 sensing, generation of a stimulus, and signal transduction that alters upstream arteriolar tone. Although actively debated, this process has been theorized to be induced by hypoxia and to involve activation of endothelial inwardly rectifying K+ channels (KIR) 2.1 by elevated extracellular K+ to trigger conducted hyperpolarization via connexin40 (Cx40) gap junctions to upstream resistors. This concept was tested in resting healthy skeletal muscle of Cx40-/- and endothelial KIR2.1-/- mice using state-of-the-art live animal imaging where the local tissue O2 environment was manipulated using a custom gas chamber. Second-by-second capillary RBC flow responses were recorded as O2 was altered. A stepwise drop in PO2 at the muscle surface increased RBC supply in capillaries of control animals while elevated O2 elicited the opposite response; capillaries were confirmed to express Cx40. The RBC flow responses were rapid and tightly coupled to O2; computer simulations did not support hypoxia as a driving factor. In contrast, RBC flow responses were significantly diminished in Cx40-/- mice. Endothelial KIR2.1-/- mice, on the other hand, reacted normally to O2 changes, even when the O2 challenge was targeted to a smaller area of tissue with fewer capillaries. Conclusively, microvascular O2 responses depend on coordinated electrical signaling via Cx40 gap junctions, and endothelial KIR2.1 channels do not initiate the event. These findings reconceptualize the paradigm of blood flow regulation in skeletal muscle and how O2 triggers this process in capillaries independent of extracellular K+.